Purpose <p>The need for long-term intravitreal anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) may be challenging for patients and providers, potentially resulting in lapses in care. The global Barometer survey examined barriers and opportunities for improvement for nAMD management from different perspectives; this article reports findings for Germany.</p> Methods <p>Data were gathered from 4 academic tertiary hospitals in Germany. Likert-scale questions captured perspectives from 200 patients with nAMD and 38 ophthalmologists (providers).</p> Results <p>Communication between patients and providers was positively perceived, with 90% of patients reporting that they felt comfortable asking questions. Most patients reported a general understanding of nAMD and the treatment required. However, 49% did not know how long treatment would be required. Structural barriers such as difficulties in travelling to the clinic and long waiting times were reported by 29% of patients. Individual concerns about being burdensome to family and fear that the treatment might not work were reported by 33% and 31% of patients, respectively. As potential improvements, 72% of patients reported a desire for more individualized discussions regarding treatment challenges, and 57% reported that longer intervals between treatments without vision loss would be beneficial. Overall, responses from patients and providers suggest a need for more structured, ongoing communication to support understanding, engagement, and adherence.</p> Conclusion <p>German results from the Global Barometer Survey identified gaps in patient education, patient expectations and logistical support for nAMD care. Addressing these issues through better communication and longer-acting treatments could improve adherence, satisfaction and outcomes.</p>